Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Fireworks: Shire Buys Jerini For €328 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”

You may also be interested in...



Persistence, Secondary Endpoints Helped Shire Get FDA Nod For Firazyr Novel PRO

FDA questioned the validity of icatibant’s patient-reported outcomes instrument during a first-cycle review and found it “difficult to interpret.” But conducting a third trial and running validity testing after FDA issued final PRO guidance, as well as key secondary endpoints that supported the treatment effect, helped sway regulators.

Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling

An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.

Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling

An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.

Related Content

Topics

UsernamePublicRestriction

Register

PS068162

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel